Compare Novartis with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GLENMARK PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GLENMARK PHARMA NOVARTIS/
GLENMARK PHARMA
 
P/E (TTM) x 674.9 7.8 8,610.7% View Chart
P/BV x 20.3 1.0 2,023.3% View Chart
Dividend Yield % 2.2 1.0 216.9%  

Financials

 NOVARTIS   GLENMARK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
GLENMARK PHARMA
Mar-19
NOVARTIS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs980712 137.7%   
Low Rs600484 124.1%   
Sales per share (Unadj.) Rs198.7349.6 56.8%  
Earnings per share (Unadj.) Rs21.032.8 64.0%  
Cash flow per share (Unadj.) Rs22.344.3 50.2%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.3 378.2%  
Book value per share (Unadj.) Rs307.5198.6 154.8%  
Shares outstanding (eoy) m24.69282.17 8.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.7 232.6%   
Avg P/E ratio x37.718.2 206.7%  
P/CF ratio (eoy) x35.513.5 263.4%  
Price / Book Value ratio x2.63.0 85.4%  
Dividend payout %47.76.1 781.7%   
Avg Mkt Cap Rs m19,508168,625 11.6%   
No. of employees `0000.612.0 4.8%   
Total wages/salary Rs m1,17120,561 5.7%   
Avg. sales/employee Rs Th8,445.48,196.0 103.0%   
Avg. wages/employee Rs Th2,015.71,708.1 118.0%   
Avg. net profit/employee Rs Th891.0768.5 116.0%   
INCOME DATA
Net Sales Rs m4,90798,655 5.0%  
Other income Rs m7832,081 37.6%   
Total revenues Rs m5,689100,736 5.6%   
Gross profit Rs m12315,858 0.8%  
Depreciation Rs m323,259 1.0%   
Interest Rs m163,346 0.5%   
Profit before tax Rs m85811,335 7.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m3403,756 9.1%   
Profit after tax Rs m5189,250 5.6%  
Gross profit margin %2.516.1 15.6%  
Effective tax rate %39.633.1 119.6%   
Net profit margin %10.69.4 112.5%  
BALANCE SHEET DATA
Current assets Rs m8,05566,968 12.0%   
Current liabilities Rs m1,85040,211 4.6%   
Net working cap to sales %126.427.1 466.2%  
Current ratio x4.41.7 261.4%  
Inventory Days Days4583 54.0%  
Debtors Days Days3481 41.8%  
Net fixed assets Rs m15033,322 0.4%   
Share capital Rs m123282 43.7%   
"Free" reserves Rs m7,46955,770 13.4%   
Net worth Rs m7,59256,052 13.5%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m9,824132,888 7.4%  
Interest coverage x54.94.4 1,252.2%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.7 67.3%   
Return on assets %5.49.5 57.3%  
Return on equity %6.816.5 41.3%  
Return on capital %11.517.8 64.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5862,998 0.1%   
Fx outflow Rs m1,32622,859 5.8%   
Net fx Rs m-1,26940,140 -3.2%   
CASH FLOW
From Operations Rs m-1,94313,242 -14.7%  
From Investments Rs m2,742-6,990 -39.2%  
From Financial Activity Rs m-298-7,387 4.0%  
Net Cashflow Rs m501-2,971 -16.9%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 6.9 29.0%  
FIIs % 1.6 34.4 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.5 204.8%  
Shareholders   41,647 56,727 73.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Mar 27, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS